Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Y2IH
|
||||
Former ID |
DNC004038
|
||||
Drug Name |
LY-255283
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Asthma [ICD10:J45] | Terminated | [1], [2] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C19H28N4O3
|
||||
InChI |
InChI=1S/C19H28N4O3/c1-5-15-16(13(2)24)11-14(25)12-17(15)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
|
||||
InChIKey |
VSDBVKWYFGKZPY-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Leukotriene B4 receptor 1 | Target Info | Inhibitor | [3] | |
Leukotriene B4 receptor 2 | Target Info | Inhibitor | [3] | ||
KEGG Pathway | Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
Reactome | Leukotriene receptors | ||||
G alpha (q) signalling eventsR-HSA-391906:Leukotriene receptors | |||||
G alpha (q) signalling events | |||||
WikiPathways | Nucleotide GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
Spinal Cord Injury | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3351). | ||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001833) | ||||
REF 3 | J Med Chem. 1993 Nov 26;36(24):3978-81.o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.